Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Newland

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Hematology (Amsterdam, Netherlands)|October 5, 2019
A systematic literature review on the use of platelet transfusions in patients with thrombocytopeniaAdrian Newland, Roy Bentley, Anna Jakubowska, et al.
American Journal of Hematology|March 5, 2020
Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trialsDavid J Kuter, Donald M Arnold, Francesco Rodeghiero, et al.
American Journal of Hematology|July 2, 2009
Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531)Vinod A Pullarkat, Terry B Gernsheimer, Jeffrey S Wasser, et al.
European Journal of Haematology|June 7, 2022
Incidence of adult primary immune thrombocytopenia in England-An updateIndraraj Umesh Doobaree, Katherine Conway, Haroon Miah, et al.
Blood|October 24, 2008
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic reviewRoberto Stasi, Ameet Sarpatwari, Jodi B Segal, et al.
British Journal of Haematology|February 23, 2019
Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studiesDavid J Kuter, Adrian Newland, Beng H Chong, et al.
British Journal of Haematology|October 26, 2006
An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpuraAdrian Newland, Marie T Caulier, Mies Kappers-Klunne, et al.
Hematology (Amsterdam, Netherlands)|October 11, 2023
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study)A J Gerard Jansen, Vickie McDonald, Adrian Newland, et al.
British Journal of Haematology|February 26, 2013
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacyDavid J Kuter, James B Bussel, Adrian Newland, et al.
Hematology (Amsterdam, Netherlands)|September 8, 2023
Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohortAlessandro Lucchesi, Barbara Lovrencic, Vickie McDonald, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Hematology (Amsterdam, Netherlands)|October 5, 2019
A systematic literature review on the use of platelet transfusions in patients with thrombocytopeniaAdrian Newland, Roy Bentley, Anna Jakubowska, et al.
American Journal of Hematology|March 5, 2020
Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trialsDavid J Kuter, Donald M Arnold, Francesco Rodeghiero, et al.
American Journal of Hematology|July 2, 2009
Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531)Vinod A Pullarkat, Terry B Gernsheimer, Jeffrey S Wasser, et al.
European Journal of Haematology|June 7, 2022
Incidence of adult primary immune thrombocytopenia in England-An updateIndraraj Umesh Doobaree, Katherine Conway, Haroon Miah, et al.
Blood|October 24, 2008
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic reviewRoberto Stasi, Ameet Sarpatwari, Jodi B Segal, et al.
British Journal of Haematology|February 23, 2019
Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studiesDavid J Kuter, Adrian Newland, Beng H Chong, et al.
British Journal of Haematology|October 26, 2006
An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpuraAdrian Newland, Marie T Caulier, Mies Kappers-Klunne, et al.
Hematology (Amsterdam, Netherlands)|October 11, 2023
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study)A J Gerard Jansen, Vickie McDonald, Adrian Newland, et al.
British Journal of Haematology|February 26, 2013
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacyDavid J Kuter, James B Bussel, Adrian Newland, et al.
Hematology (Amsterdam, Netherlands)|September 8, 2023
Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohortAlessandro Lucchesi, Barbara Lovrencic, Vickie McDonald, et al.
Pageof 5